China Resources Boya Bio pharmaceutical Group Co Ltd Cash Flow-to-Debt Ratio
China Resources Boya Bio pharmaceutical Group Co Ltd cash flow-to-debt ratio. China Resources Boya Bio pharmaceutical Group Co Ltd (300294) has a Cash Flow-to-Debt Ratio of 0.03x as of December 2025, meaning its operating cash flow of CN¥36.82 Million could theoretically repay 0% of its total liabilities (CN¥1.16 Billion) in one year. Check China Resources Boya Bio pharmaceutical earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of China Resources Boya Bio pharmaceutical Group Co Ltd (2009–2025)
Cash flow-to-debt ratio of China Resources Boya Bio pharmaceutical Group Co Ltd from 2009 to 2025. Historical debt coverage capacity for China Resources Boya Bio pharmaceutical Group Co Ltd across 17 annual periods. Check China Resources Boya Bio pharmaceutical (300294) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
China Resources Boya Bio pharmaceutical Group Co Ltd Cash Flow-to-Debt Ratio by Year (2009–2025)
China Resources Boya Bio pharmaceutical Group Co Ltd cash flow-to-debt ratio by year from 2009 to 2025. Year-by-year debt coverage analysis for China Resources Boya Bio pharmaceutical Group Co Ltd. For the full cash flow conversion analysis, see 300294 cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.10x | CN¥116.69 Million | CN¥1.16 Billion | ▼ -69.5% |
| 2024 | 0.33x | CN¥299.78 Million | CN¥913.38 Million | ▼ -74.0% |
| 2023 | 1.26x | CN¥641.73 Million | CN¥508.07 Million | ▲ +58.5% |
| 2022 | 0.80x | CN¥596.44 Million | CN¥748.35 Million | ▼ -58.5% |
| 2021 | 1.92x | CN¥1.35 Billion | CN¥701.30 Million | ▲ +157.9% |
| 2020 | 0.74x | CN¥718.58 Million | CN¥966.08 Million | ▲ +923.7% |
| 2019 | -0.09x | CN¥-114.51 Million | CN¥1.27 Billion | ▼ -437.0% |
| 2018 | 0.03x | CN¥34.90 Million | CN¥1.30 Billion | ▲ +233.4% |
| 2017 | -0.02x | CN¥-23.82 Million | CN¥1.19 Billion | ▼ -102.9% |
| 2016 | 0.69x | CN¥198.76 Million | CN¥287.30 Million | ▲ +31.8% |
| 2015 | 0.52x | CN¥147.02 Million | CN¥280.11 Million | ▼ -59.6% |
| 2014 | 1.30x | CN¥121.88 Million | CN¥93.90 Million | ▲ +129.9% |
| 2013 | 0.56x | CN¥89.11 Million | CN¥157.85 Million | ▼ -84.2% |
| 2012 | 3.58x | CN¥92.36 Million | CN¥25.80 Million | ▲ +200.7% |
| 2011 | 1.19x | CN¥81.53 Million | CN¥68.48 Million | ▲ +370.1% |
| 2010 | 0.25x | CN¥24.77 Million | CN¥97.79 Million | ▼ -25.8% |
| 2009 | 0.34x | CN¥51.88 Million | CN¥151.93 Million | — |